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Abstract
Research in psychopharmacology for children and adolescents is fraught with ethical problems and
tensions. This has practical consequences as it leads to a paucity of the research that is essential to
support the treatment of this vulnerable group. In this article, we will discuss some of the ethical
issues which are relevant to such research, and explore their implications for both research and
standard care. We suggest that finding a way forward requires a willingness to acknowledge and
discuss the inherent conflicts between the ethical principles involved. Furthermore, in order to
facilitate more, ethically sound psychopharmacology research in children and adolescents, we
suggest more ethical analysis, empirical ethics research and ethics input built into
psychopharmacological research design.
Introduction
"It is the duty of the physician in medical research to protect the
life, health, privacy, and dignity of the human subject." [1]
Ethics is an important issue in psychopharmacological
research, especially for research amongst vulnerable
patient populations. Research involving legal minors is
often difficult because of the complexities of consent from
legal minors and the emphasis on the protection of chil-
dren and adolescents. The research into pharmacological
treatments for children and young people with mental
disorders is particularly fraught, because of the ethical
issues surrounding research in what is in effect a doubly
vulnerable group of individuals. Unfortunately, these dif-
ficulties often become barriers to conducting research
with this group and pharmaceutical companies may pre-
fer not to fund such research, giving rise to the current
paucity of good research evidence. However, the lack of a
good evidence base upon which to treat this vulnerable
group is itself ethically reprehensible.
In this article, we will look at the background of ethics of
research, the premise of research and the central ethical
dilemmas and contradictions which affect paediatric
psychopharmacology research. We will then touch on
each of several issues which complicate the ethical
dilemmas for psychopharmacology research in children
and young people in practice: the premise of research,
consent and competence, dilemmas of inequalities of
healthcare provision, the impact of research design and
the requirement for 'minimal risk' and 'benefit', and
influences of commercial interests. We will suggest that
the way forward is to face squarely the reasons for the
restrictions placed on psychopharmacological research
in minors and the inherent ethical tensions and contra-
dictions, to consider all the ethical issues. This, together
with a greater integration of ethical analysis and research
into psychopharmacological research methodology, can
provide a way forwards that enables good, ethically
sound research to take place.
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The relevance and legacy of history
Medical research has a dark history of abuse by physicians
of large numbers of vulnerable prisoners and ethnic
minorities in the name of (often scientifically highly dubi-
ous) medical research. As a response to these past abuses,
and the recognition of the power that those in the medical
profession in particular have over patients, ethical codes
and principles governing medical research have been
developed as early as 1964 when the Declaration of Hel-
sinki was made [1].
Since then, strict rules for medical research with human
subjects have been developed from these ethical princi-
ples in most jurisdictions. Medical researchers are legally
obliged to abide by these rules. These rules are particularly
strict for researchers conducting research amongst patient
populations which are vulnerable, for example prisoners,
legal minors, the distressed, the mentally disordered, and
those who lack competence to give consent. The historical
legacy of abusive experiments with vulnerable popula-
tions, which is the current high ethical standards and legal
requirements on researchers who want to conduct studies
with vulnerable populations, has a cruel twist. A paradox-
ical situation now exists: these populations are now so
well protected against research by rigorous regulatory
requirements for clinical trials that the standard of routine
care is much less well-founded than for the general popu-
lation as there is less research data available about safety
and efficacy of medication and other treatments.
In routine care, pharmacological interventions in children
and adolescents continue to increase. However, the pau-
city of available medications specifically licensed for use
in this age group, because of the lack of research evidence
to support licensing, means that many drugs are used 'off-
label'. 'Off-label' use means that they are used outside the
bounds of the licence granted to the drug. A drug licence
specifies the age range, medical indications and dosages
for the use of the drug, based on data on efficacy and
safety demonstrated by research. 'Off-label' use, in con-
trast, tends to rely on anecdote, personal experience of
and confidence in using the drug in question, and consen-
sus amongst colleagues. Benefit-risk evaluations of this
'off-label' use are therefore largely missing, with side
effects and long-term aspects especially yet unknown [2-
4].
'Off-label' use has now been recognized as a particular
problem for drug safety [5,6]. The rate of 'off-label' use is
especially high in pre-school children and less so in ado-
lescents, but rates are generally high in comparison with
adults [7,8]. In some countries, 'off-label' use poses a
problem with regard to funding of treatment as health
insurers generally refuse to reimburse the costs of using
these drugs outside the indications of the licence [9].
Another legal and ethical aspect of 'off-label' use is who
carries the responsibility for liability in the case of side
effects or other adverse events [10].
It is an ethical conundrum that the need to protect vulner-
able populations against research has the consequence of
generating a lower standard of safety in routine care for
these very patients, who arguably deserve more protection
and less exposure to risk in the course of their medical
treatment. Research and clinical studies are therefore
urgently required in order to reduce the high rate of 'off-
label' medication use in minors and improve safety [11].
These aspects of safety, dosage and the long- and short-
term side effects of drugs in children and adolescents – as
well as the use of these drugs during pregnancy – are fre-
quently discussed, and the consensus is that the state of
research at this time is insufficient [12]. At present the
state of knowledge on both the safety and efficacy of psy-
chotropic drugs in children and adolescents and the qual-
ity of the ethical standards varies according to the age of
the patients. Again, there is a paradox that the younger the
children, the more limited our knowledge and the more
uncertain the benefits and risks of 'off-label' use. This is
because the younger the age group, the greater the vulner-
ability and therefore the greater the difficulties of conduct-
ing research, and the greater the differences between a
child's physiology and an adult's and therefore the less the
likelihood that adult research results may be informative.
Therefore the younger and more vulnerable the child, the
less able clinicians are to uphold the ethical standards
behind the paradigms of benefiting the patient and doing
no harm [13].
As these problems have become increasingly recognized
over the last decade, the feasibility and efficacy of using
legislation to increase the availability of approved and
safe drugs for children has been discussed in the USA
and Europe. In the USA, special legal regulations have
been in existence since the 1990s to encourage the devel-
opment of paediatric medications by granting further
years of patent protection to pharmaceutical companies
in return for studies in the paediatric population [14].
This appears to have had the intended effect. Indeed,
neuropharmacological medications comprise 11% of all
patent protection granted for paediatric studies. Unfor-
tunately, these regulations have not been without prob-
lems [15]. Several studies on paediatric depression were
hurriedly conducted in the USA under the pressure of
time before the legislation ran out. As a result, these
studies are methodically flawed [16]. In Europe, similar
legislation has been in effect since 2007, but the impact
of the 'EU Regulation on medicinal products for use in
children' has yet to be seen [17].Child and Adolescent Psychiatry and Mental Health 2008, 2:39 http://www.capmh.com/content/2/1/39
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The underlying premises of medical research
The historical context in which psychopharmacological
research in children and adolescents takes place has been
important in shaping the dilemmas of the current situa-
tion. However, the best way to consider the ethical issues
in order to find a way forward is not merely to sketch out
the problems as they currently exist, but to conduct an
analysis of the ethical dilemmas present. The first place to
begin the ethical analysis of psychopharmacology
research in minors is to lay out the underlying premises of
both medical research and the ethical principles that gov-
ern its oversight. We would suggest that, when simplified,
the ethical reasoning for most interventional research is
generally as follows and is represented in most codices
concerning research such as the Declaration of Helsinki by
the WMA, the National Commission for the Protection of
Human Subjects of Biomedical and Behavioral Research
which published in 1976 their report about research on
prisoners, and in 1979 the Belmont Report [1,18]. Most
other codices or regulations rely on these 'basic' codices.
1. The medical profession has a duty to treatment each
patient in his or her best interests, by offering the best
treatment available and knowing what is the best as well
as the safest treatment for the patient's condition – this is
Duty of Care, [1] (see Appendix 1),
2. Research is therefore required to provide the knowledge
base in order to fulfil our Duty of Care to our patients [1]
(see Appendix 2);
3. Where possible we should do research without using
human subjects but in many cases we do have to use
human subjects;
4. If we do research in patients, we should only involve
vulnerable patients if there is no alternative group that can
be used and the research is necessary [19] (see Appendix
3);
5. For a vulnerable patient group, protection in their best
interests is the rule. Even when such patients give consent
or assent, research should only be permitted if it causes
minimal harm or distress and has the potential to benefit
each patient in the future or others with the same condi-
tion. Along the same lines of protection in best interests,
only therapeutic research that has a clear prospect of ben-
efiting the individual participant to at least the same
extent of the current alternative treatments is permitted to
carry more than a minimal risk of harm or distress to sub-
jects [19-21] (see Appendix 4).
6. But: research always has its own risks of harm and
research is only justified if there is uncertainty in the out-
come, harm or benefit which needs to be determined,
which means that may be as much likelihood of harm or
lack of benefit from participation as there is likelihood of
benefit;
7. Furthermore, research designs and research physicians
are inherently unable to prioritise the interests of the indi-
vidual participant to the same extent as in normal medical
care because their primary objective is to answer a research
question and they must follow research protocols;
8. Therefore taking part in research can never really be in
the best interests of an individual patient as compared to
the best current standard of care.
We therefore come to another paradox – it is clearly in the
interests of all patients, to have more research take place
in order to provide the knowledge to underpin their care,
but particularly patients with conditions or in situations
which are under-researched; but, it is in theory rarely, if
ever, in the interests of an individual patient to take part
in research as opposed to getting the best standard of indi-
vidual care. This paradox means that for an individual
patient, the best outcome is achieved by refusing to take
part in research but making sure everyone else agrees. This
is clearly not feasible, nor is the reality of running trials
and taking part in them as clear cut. Nevertheless, it is
important to realise that the underlying ethical premise of
research participation already contains some inherent
internal contradictions.
Living in the real world
There are difficulties with respect to research participation
in terms of conflict in ethical principles. The real world is
even more complicated, as there are departures in the real
world from the assumptions made above. These can
broadly be divided into three different categories – con-
straints due to limitations in access to medical care, con-
straints due to research design, and constraints due to
commercial interests in medical research. Furthermore,
the impact of research can be felt not just in terms of the
condition and the effects under study. Impact can be
found in terms of other aspects of the patient himself, for
example his psychological and physical wellbeing; and
also his relationships with others and his activities, for
example his ability to relate to his family and his ability to
learn at school. Therefore any benefit of study may not be
limited to the immediate study conditions but has to be
analysed in the context of the environment of the patient.
The concept of 'benefit' is problematic, as will be dis-
cussed later.
In many real life research situations, some treatments
undergoing research would be relatively new and may not
be publicly funded nor yet licensed for general use. For
some patients, for instance those who have failed toChild and Adolescent Psychiatry and Mental Health 2008, 2:39 http://www.capmh.com/content/2/1/39
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respond to conventional treatment or suffer from disor-
ders with no effective treatment, there may be strong
inducement to take part in research in order to gain access
to the treatment in question. Balanced against this is the
argument that research is inherently more beneficial to
the individual in these cases, because without the exist-
ence of the research study the patients would simply be
denied the possibility of being given those treatments in
their standard care.
In some cases where medication is already in general use,
research participation can nevertheless be extremely ben-
eficial to the individual participants. For example, it has
been found that participation in clinical research increases
survival for breast cancer patients [22]. This can happen
because of the 'real world' of managed healthcare systems,
or healthcare systems constrained by limited or uneven
distribution of resources. In these non-ideal healthcare
systems, some people may not be able to access the best
standard of treatment. This occurs in many settings, for
example in remote areas in developing countries, and also
in areas of poverty and deprivation within industrialised
countries. Although such patients would not be getting
the best possible individualised care by taking part in
research, research protocols tend to guarantee good access
to high quality care, support and monitoring for all partic-
ipants at no financial cost to them.
Pragmatically, it would certainly appear more ethically
justifiable to allow research participation if this provides
better care than participants would otherwise obtain.
However, there could be real concern that this could be a
coercive situation if research participation constitutes the
best or, worse, the only recourse to treatment for an indi-
vidual. In such cases there would be undue inducement
and little perceived choice concerning research participa-
tion, and decisions concerning research participation are
unlikely to be altruistic in nature but driven by necessity.
Such patients may be left particularly vulnerable, for
example, they may not feel able to withdraw from the
study because this may compromise their care, or they
may feel obligated to the researcher for his or her help.
Health inequalities can lead to differences in ethical
standards required for research in different countries and
circumstances. In countries or areas where patients may
be unable to access high quality healthcare, any research
that would provide good medical care for the people
might be argued to be highly beneficial and therefore eth-
ically permissible despite the risks involved, whereas the
identical research may not be seen as acceptable nor ben-
eficial in well-resourced areas in developed countries.
There is then a danger of injustice, that countries and
neighbourhoods where there are poorer healthcare facili-
ties may be exploited by researchers from richer countries
or institutions [23].
Another aspect of the 'real world' of pharmacological
research concerns the design of the studies conducted in
these vulnerable populations. To improve both the safety
of drugs and the quality of research in paediatrics and in
child and adolescent psychiatry, it would be essential to
consider special needs of children and adolescents and to
investigate the effects of combination therapies (psychop-
harmacotherapy and psychotherapy, treatment with sev-
eral medications) [12]. Unfortunately, this is often not
reflected in study designs and therefore the quality of
treatment in studies may not represent the state of the art
[24]. The exclusion criteria of any additional treatment or
severe co-morbidity may simultaneously represent both
best practice in terms of protection of the vulnerable and
severely ill population and a study design which provides
a suboptimal treatment strategy [14,25]. Furthermore, by
failing to represent the real life circumstances of multiple
or concurrent treatments, there are risks that research may
fail to provide realistic answers that are helpful to clini-
cians who need to interpret research results and apply
them to their clinical practice.
There are other aspects to living in the real world – the
nature of other vested interests, such as commercial inter-
ests, in pharmacological research. These will be discussed
in a later section.
Issues of consent and competence
There are two basic ways of considering the ethics of any
issue. One is to judge the rightness or morality of any
action by the degree of good or harm that results from it,
known as utilitarianism; the other is to judge the rightness
or morality of any action by how much it conforms with
the generally (often tacitly) accepted ethical principles. In
general, justifying actions only by outcome alone is not
sufficient, as demonstrated by several international con-
ventions regarding human rights which articulate ethical
principles concerning rights and duties. With regard to
children and adolescents, as legal minors, consent is an
area where several different ethical principles can conflict:
￿ The principle of autonomy suggests that individuals
who are competent (that is, able to make their own deci-
sions) should generally give consent for their own treat-
ment. There is an ethical obligation to involve all children
in decision-making, according to their maturity. In the
legal regulations the obligation of parents to involve their
children in decision-making is defined in a way similar to
the Convention of Human Rights and Biomedicine of the
European Council: the will and the mind of the minor
"shall be taken into consideration as an increasingly determin-Child and Adolescent Psychiatry and Mental Health 2008, 2:39 http://www.capmh.com/content/2/1/39
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ing factor in proportion to his or her age and degree of matu-
rity."  (Article 6, Convention of Human Rights and
Biomedicine [26]).
￿ The principle of best interests, however, suggests that
patients, in particular vulnerable patients, should be pro-
tected in their best interests, whatever their treatment
decisions are. (Article 3: 1, UN Convention of the Rights
of the Child [27]: "In all actions concerning children, whether
undertaken by public or private social welfare institutions,
courts of law, administrative authorities or legislative bodies,
the best interests of the child shall be a primary consideration.")
￿ A further principle of protection of children suggests
that legal minors are in greater need of protection than
other individuals by virtue of their relative immaturity,
irrespective of whether they are competent to make their
own treatment decisions; therefore they should not be
permitted to make major decisions which will seriously
harm them (Article 3: 2, UN Convention of the Rights of
the Child [27]: "States Parties undertake to ensure the child
such protection and care as is necessary for his or her well-
being, taking into account the rights and duties of his or her
parents, legal guardians, or other individuals legally responsible
for him or her, and, to this end, shall take all appropriate legis-
lative and administrative measures.")
￿ There is also a relatively little discussed principle of
parental responsibility, which gives parents responsibility
for the welfare of their children and therefore a (limited)
right to be involved in children's decisions, where it is rel-
evant and necessary to their role as parents, depending on
the child's state of development and dependency (see Arti-
cle 3:2 above and Article 18:1. "States Parties shall use their
best efforts to ensure recognition of the principle that both par-
ents have common responsibilities for the upbringing and devel-
opment of the child. Parents or, as the case may be, legal
guardians, have the primary responsibility for the upbringing
and development of the child. The best interests of the child will
be their basic concern.").
￿ And finally, there is a principle of the importance of
family relationships, expressed in the European Conven-
tion for Human Rights as 'a right to family life', where
both children and parents have a right to family life and
the relationships involved (Council of Europe Conven-
tion for the Protection of Human Rights and Fundamental
Freedoms as amended by Protocol No. 11, Article 8 Right
to respect for private and family life [28]: "Everyone has the
right to respect for his private and family life, his home and his
correspondence.")
Negotiating the issue of consent involves balancing all
these different and often opposing principles. Very young
children lack the understanding to make their own deci-
sions, so parents usually make decisions for them, and are
expected to do so in their best interests. As children
develop, their parents and other adults begin to foster
their autonomy, so that children should be increasingly
able to make, and allowed to make, more decisions for
themselves, in proportion to their maturity and the
importance of the decisions. Whereas the autonomy of
the young child may be less developed, autonomy and the
right to autonomous decision-making increases with age
as children mature emotionally and intellectually. Chil-
dren's (and adolescents') rights with regard to decision-
making have to be balanced against their ability to deal
with the responsibilities that come with it (see Appendix
5). Therefore we can see the autonomy of decision making
in minors as a continuum between the extremes of no
autonomy and of total autonomy of the minor (see Figure
1) [29]. Parallel to this, their parents have responsibilities
with regard to decision-making to an extent that is
inversely proportional to whether their children are able
to make decisions for themselves. These responsibilities
endow the parents with rights to information about their
children as appropriate to their involvement.
When children and young people suffer from mental or
physical disorders, they become more vulnerable and the
issue of protection becomes more important. Because of
this vulnerability, the emphasis on protection tends to be
greater for research in legal minors, and it is standard for
Institutional Research Boards (usually known as IRBs,
which are ethics oversight committees) to insist on
informed consent from parents as well as assent or con-
sent from the child or young person for participation in
research, which is a higher standard for consent than
required for standard treatment. This insistence on paren-
tal involvement can be ethically problematic for compe-
tent young people who may be taking part in research that
Levels of autonomy and participation of minors in decision  making Figure 1
Levels of autonomy and participation of minors in decision 
making.Child and Adolescent Psychiatry and Mental Health 2008, 2:39 http://www.capmh.com/content/2/1/39
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involves discussing sensitive topics, for example illicit
drug use and suicidal intent.
Another area that can be problematic is that of compe-
tence. Competence is usually conceptualised as a largely
cognitive skill which should be assessed for each specific
decision. A person may possess competence to make one
sort of decision even if he or she lacks it to make another.
There are slightly varying definitions of competence in
various legislations as well as various ethical analyses, but
in general these include:
￿ the ability to understand the relevant information;
￿ the ability to retain the information long enough to
arrive at a decision;
￿ the ability to appreciate its application to oneself;
￿ the ability to weigh the facts in the balance in order to
come to a decision;
￿ the ability to reason about the treatment options;
￿ the ability to communicate a choice [30] (see Appendix
6).
Research has shown that children have the competence to
make most treatment decisions by the age of 9 years when
given simplified information, and by the age of 14 years
when given adult-level information [31]. This would sug-
gest that even relatively young children should be able to
make their own decisions. However, research has also
shown that children and adolescents can have other prob-
lems with making autonomous decisions [32]. They are
more sensitive to the views of the adults around them and
susceptible to pressure as well as worries about offending
researchers and parents if they change their minds. Having
a mental disorder can have an additional impact upon
treatment decision-making for children and adolescents.
In some cases, they can become more vulnerable and
regress in terms of needing more parental support for
decisions they may ordinarily be able to make. Having a
mental disorder can have complex effects on autonomy.
For example, research suggests that having an eating dis-
order may distort their sense of identity, values, goals in
life and sense of their future [33,34]. Research also sug-
gests that children with attention-deficit/hyperactivity dis-
order may be influenced by values or hopes of gaining
their parents' confidence when deciding whether to par-
ticipate in a trial which offers them the chance to improve
behaviour [Koelch M, Burkert J, Prestel A, Singer H,
Schulze U, Fegert JM. The MacArthur Competence Assess-
ment Tool for Clinical Research (MacCAT-CR) in child
and adolescent psychiatry. General remarks about the fea-
sibility of the instrument in a special population. Journal
of Child and Adolescent Psychopharmacology 2008, sub-
mitted].
Even if they have competence to make decisions, because
of their close relationships with their parents, many chil-
dren and adolescents may prefer to have a group or joint
decision-making model, making decisions together with
parents and other trusted adults. Children and adoles-
cents who are suffering from mental disorders are proba-
bly more likely to prefer, and benefit from, a joint
decision-making model [35].
The concept of benefit
Regulations governing interventional research in vulnera-
ble groups such as children and adolescents generally
demand that the intervention should benefit the research
participant, and pose either or both minimal risk and
minimal burden; or, if the risks or burden are greater than
minimal, that the participant must obtain a significant
benefit at least equivalent to that of standard treatment.
Unfortunately, all three concepts of 'benefit', 'minimal
risk' and 'minimal burden' are problematic both in terms
of the underlying ethical issues as well as definition.
The concept of benefit is deceptively simple. The 'benefit'
of a study or of the participation in the study is a measure
that resists dichotomisation, so that it can be difficult to
be certain whether a person does or does not benefit from
research participation. Instead, there is usually a spectrum
of magnitudes of potential or actual 'benefit', which can
be perceived differently from the perspectives of the
researcher, the study outcomes, and the patient. Further-
more, the measurement of benefit can be difficult, as there
are three distinct dimensions on which benefit of partici-
pation in a study may be measured. These are the proba-
bility, the magnitude and the sustainability of benefit
[36]. The nature of probability is that even if it is consid-
ered likely that participants will benefit from research par-
ticipation, some individuals may fail to benefit.
Magnitude of benefit may vary between participants as
well as between studies, and benefit may occur in many
different aspects, including some which may be unex-
pected or difficult to measure. Finally, sustainability of
benefit may vary between studies, with some having
immediate but short-lived benefit, while others have
longer term or even late-onset benefit.
Benefit, therefore, is difficult to define and measure. Ben-
efit has to be assessed both for a study in general terms,
and also for the individual study interventions, the study
design and investigations or examinations. Benefit has to
be further weighed up for each patient in the context of his
individual perceptions and values, life situation and stage
of disease.Child and Adolescent Psychiatry and Mental Health 2008, 2:39 http://www.capmh.com/content/2/1/39
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The concepts of minimal risk and minimal 
burden
Because of the emphasis on the protection of children and
young people, Institutional Research Boards (IRBs) often
insist that many protective mechanisms are built into
interventional medicinal trials, and research that involves
more than a small amount of risk tends to be rejected. In
a recent directive, the European Parliament required that
'minimal risk' should be the standard for research trials in
children [19]. In this directive, there is a requirement that
"medicinal products for trial may be administered to all such
individuals only when there are grounds for assuming that the
direct benefit to the patient outweighs the risks". A prerequi-
site for research is that "some direct benefit for the group of
patients is obtained from the clinical trial and only where such
research is essential to validate data obtained in clinical trials
on persons able to give informed consent or by other research
methods; additionally, such research should either relate
directly to a clinical condition from which the minor concerned
suffers or be of such a nature that it can only be carried out on
minors". As the directive must be implemented by mem-
bers of the European Union in national law, each member
state will have to adapt these sentences into its own law.
The definition of this notion of 'minimal risk' is problem-
atic. There are variations in the definition across countries:
￿ In the United States (The Common Rule, 1991):
- " [risks] ordinarily encountered in daily life or during the per-
formance of routine physical or psychological examinations or
tests"
￿ In Canada (2005):
- "no greater than those encountered by the subject in those
aspects of his or her everyday life that relate to the research"
￿ In Europe – the Council of Europe (2005) (minimal risk
and minimal burden):
- "very slight and temporary negative impact on the [person's]
health" and "discomfort [i.e., burden] will be temporary and
very slight"
￿ In the United Kingdom (2004):
- "procedures such as questioning, observing, and measuring
children [and] obtaining bodily fluids without invasive inter-
vention; [no] more than a very slight and temporary negative
impact on [child's] health"
- Low risk: "might cause no more than brief pain or tenderness,
small bruises or scars, or very slight, temporary distress; e.g., a
blood test"
￿ In Germany (German Drug Code: 12. Amendment Ger-
man Drug Code §41 (2), 2004):
- "If it is expected that the intervention at most leads to a very
slight and temporary impairment of the health of the subject.
Minimal burden is seen if the intervention causes discomfort
which is at the most temporary and very slight."
There is some conceptual confusion around the idea of
'minimal risk'. Is 'minimal risk' supposed to mean 'mini-
mal distress and suffering'? This interpretation has some
merit, as we would wish to inflict minimal pain and dis-
tress, irrespective of benefit or risk, particularly for non-
consenting individuals such as babies and young children
who would have little or no appreciation of the research
rationale or benefits. Or is 'minimal risk' instead sup-
posed to mean 'not much greater risk of harm as com-
pared to ordinary life and ordinary treatment'? This
alternative interpretation also has merit, particularly
when looking at the issue of preserving the best interests
of the vulnerable participant. The two definitions would
overlap in real life, but are conceptually distinct. For
example, a procedure producing a great deal of benefit
and relatively little medium to long term harm may be
very distressing to an individual. Yet, another procedure
exposing an individual to much greater risk of harm than
he or she would ordinarily experience may evoke little dis-
tress or suffering. Also, the standard treatment may cause
considerable distress and side effects, and the alternative
research treatment may have greater risks in terms of hav-
ing less benefit and more toxic effects, but be a great deal
more pleasant than the currently available treatment.
What are study procedures which can be considered as
minimal burden for the patient or have minimal risk for
him? Examples that have been given in the regulations for
minimal risk and burden are measuring, weighing, and
the drawing additional a minimal quantum of blood by
an already existing venous access. However, even single
and small additional blood drawing may be already a risk
which is increased over minimal risk, if the standard treat-
ment has already required a large number of blood draw-
ings or a large volume. Also a repetitive examination
which would count in case of a single procedure as a min-
imal burden may be more than a minimal burden if it is
conducted with a high frequency.
The variation between countries about whether they inter-
pret 'minimal risk' to mean lower distress, lower risk, or
both, means that there will be confusion about what risk
is considered acceptable, and little consistency of the eth-
ical standards adopted by research studies across these
countries.Child and Adolescent Psychiatry and Mental Health 2008, 2:39 http://www.capmh.com/content/2/1/39
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The minimal risk has to be examined in the individual
case of each study and indeed each patient. There is no
final agreement about the terms and therefore a discus-
sion in study teams and Institutional Research Boards
(IRBs) may lead to a different consensus for each individ-
ual study. This may disconcert researchers who cannot
refer to a standard, but this reflects the general difficulties
of applying ethics in research, that general rules are often
difficult if not impossible to provide. The researcher him-
self has the obligation to consider the ethical aspects of
the study he plans, and to be prepared to justify his
approach. The differences in national guidelines and laws
in their definition of minimal risk and burden also
requires an individual discussion of study procedures
within each jurisdiction to ensure conformity with
national law and its interpretation [37,38].
Ethical issues in research design
There are two different but related ways in which research
design can be ethically problematic:
1. when the design itself may raise ethical concerns, for
example when participants may be at risk or even harmed
(see discussion above of benefit and risk); and
2. when the design is scientifically sub-optimal, which
makes it ethically dubious because we should not subject
research participants, particularly those from vulnerable
groups, to research which may not be adding good quality
evidence to the scientific body of knowledge.
The best design for testing the effect of pharmacological
interventions is the randomised controlled trial of a drug
against a placebo control (E.g., [12,39,40]), Unfortu-
nately, except in the increasingly rare situations where
there are no drugs which are in general use or have any
known efficacy for the disorder, there are serious ethical
issues involved in subjecting participants to a placebo
control because this effectively means denying them
active treatment for the duration of the trial. There have
been some research designs which attempt to compensate
for this, for example double cross-over trials. However,
even this can only be done in a limited number of disor-
ders, for example those where a period without treatment
is considered safe.
Limitations in research design can lead to serious difficul-
ties. In adolescent psychiatry, most of the drug trials
involving Selective Serotonin Reuptake Inhibitor (SSRIs)
pitted one SSRI against another, but almost all have been
discredited because of failures to report adverse events
such as suicide (see Figure 2) [41-44]. This has left the evi-
dence base very shaky and the withdrawal of all except
one SSRI, Fluoxetine, for the treatment of depression in
adolescents.
Another way in which research design may be scientifi-
cally suboptimal is when the comparisons being made do
not reflect clinical reality. This is highly relevant to child
and adolescent mental health, where pharmacological
treatments are rarely used in isolation, and are usually
combined with a psychological therapy. There are, how-
ever, commercial constraints which explain why natural-
istic combined treatment trials are rarely funded and
therefore rarely conducted. This will be discussed in the
next section.
Ethical issues in commercial research interests
Pharmacological research trials are extremely expensive to
set up and run. The possibility of legislation to increase
the availability of approved and safe drugs for children
has been discussed in the USA and Europe [11,14-17,45-
47]. An essential difference exists between the US and
Europe in funding clinical trials with minors. In Europe,
given the general paucity of public research funds and the
expense of interventional trials, publicly funded pharma-
cological research is still relatively rare. Commercial phar-
maceutical companies, however, have strong vested
interests in finding their products, particularly new prod-
ucts still under patent, to be superior to other medica-
tions. The ultimate bottom line for pharmaceutical
companies, which are commercial institutions with
accountability of management to shareholders, is to cre-
ate profit. Coupled with the common problem of publica-
tion bias because trials with negative results are less
interesting and therefore harder to publish than positive
ones, this can create significant skewing of results (see for
example the problems accompanied with SSRI in chil-
dren) [48-50]. Skewed results showing a spurious effect
can alter clinical practice and potentially harm patients as
ineffective medication may be prescribed which would
Text box: 'The sad story of selective serotonin reuptake  inhibitors (SSRIs) in children and adolescents' Figure 2
Text box: 'The sad story of selective serotonin reuptake 
inhibitors (SSRIs) in children and adolescents'.
In 2004 a meta-analysis of data out of studies of SSRIs in children and adolescents 
was published by Whittington and colleagues [48]. This review revealed that most of 
these substances have no benefit but may cause harm in minors. Alarmed by reports 
in the media about suicides among youths prescribed an SSRI, official regulatory 
authorities then conducted audits of the data from pharmaceutical companies 
concerning all trials and results by these trials with minors. The major results of these 
audits were both alarming and informative. First, the pharmaceutical companies had 
published the results of trials very selectively: ‘good news’, such as data about 
effectiveness of SSRIs, was published, whereas ‘bad news’, the data about side-effects 
or inefficacy, was not published. Second, an analysis of all trials and published and 
unpublished data by Hammad and colleagues [41] revealed that there was an 
increased risk for suicidal behaviour among children and adolescents using SSRIs. 
This revelation has led to black-box warnings against all antidepressants and resulted 
in a decrease of use in some countries. The consequent decreased use is now thought 
to be responsible for an increase in suicides among youths and the FDA has been 
criticised for this outcome[42, 43]. This complex issue is discussed by Zito and Safer 
[44]  and the long-term effects of this research scandal are yet to be revealed. 
Publishing policy has changed since the SSRI debacle and journals have revised their 
policies about publishing studies showing inefficacy. Child and Adolescent Psychiatry and Mental Health 2008, 2:39 http://www.capmh.com/content/2/1/39
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expose patients to risks of medication without the bene-
fits.
Researchers who are employees of pharmaceutical compa-
nies can experience moral dilemmas between maintain-
ing scientific objectivity and the obligation to try to
produce positive results that can help their employers
achieve targets. Researchers who have their research or
teaching activities funded by pharmaceutical companies
may also experience this moral dilemma. There is a grow-
ing movement against commercially funded research and
researchers, with independent experts, researchers and
research being favoured as less biased [51,52]. In the past,
pharmaceutical companies have been lavish in funding
teaching, seminars and academic activities such as confer-
ence attendance for physicians. There is, however, evi-
dence that these commercial sponsorships have an impact
on prescribing practices of physicians [49,52-55]. There
has a growing suspicion of commercial interests as unethi-
cal and a backlash amongst doctors against pharmaceuti-
cal sponsorship and commercially funded research.
A further ethical dilemma in commercially driven research
is that where there is relatively low financial gain to be had
from conducting research, pharmaceutical companies are
less likely to fund it. This is the case for psychopharmaco-
logical research in children and adolescents. Once a new
drug is licensed for use in adults, given the lack of research
evidence for drugs in adolescents and particularly chil-
dren, child and adolescent psychiatrists will begin to pre-
scribe these drugs 'off-label' to their patients. To attempt
to conduct research in children and adolescents to obtain
licences for these age groups would be both more complex
and therefore expensive for companies, and may also pro-
vide minimal additional commercial yield.
Yet another ethically relevant point is the need for com-
bined treatment strategies in child and adolescent psychi-
atry. To improve the safety of drugs in paediatric and
adolescent psychiatry, it will be essential to consider spe-
cial needs of children and adolescents and to investigate
the effects of combination therapies (psychopharmaco-
therapy and psychotherapy, or treatment with several
medications). The really essential evidence of the last dec-
ade has been found in publicly funded trials on attention-
deficit/hyperactivity disorder (ADHD) and in depression
(major depressive disorder, or MDD). The NIMH Multi-
modal Treatment Study of ADHD (also known as the MTA
study) and the NIMH-funded Treatment for Adolescents
with Depression Study (TADS) compared both psycho-
therapy and psychopharmacotherapy with the combined
treatment, which is a more naturalistic approach than
having two solely pharmacotherapy treatment arms
[56,57].
Pharmaceutical companies have not tended to be inter-
ested in funding multimodal interventional research as
their primary interest lies in the superiority of one phar-
maceutical product over another. Furthermore, in the case
of comparing two substances from two different manufac-
turers, patent aspects may be an important hindrance.
There has therefore been little research funding from the
companies for this particularly vulnerable patient group.
The new European legislation has the potential to help
facilitate such naturalistic trials, but to what extent such
desiderata are taken into consideration by the EU regula-
tion is being critically discussed [11,58].
As much as commercial interests may affect research, it
would be even more unethical, in addition to being unfea-
sible, to discount or seek to dismiss all commercially
funded research. It is unrealistic to expect that pharmaceu-
tical research will be totally or even mainly funded by
non-commercial organisations. Nor is it realistic to expect
an altruistic attitude to research funding from commercial
companies. Nevertheless, it may be possible to persuade
commercial companies that more naturalistic multimodal
or combination therapy trials are both commercially via-
ble and advantageous. Both the TADS and the ADAPT nat-
uralistic trials have been more successful in providing
strong evidence for efficacy of drugs than previous trials
[24,59]. Convincing evidence of efficacy in naturalistic
settings is more likely to lead to greater acceptance in pre-
scribing the relevant medication. For a way forward to
solve these problems a discourse between ethicists, child
and adolescent psychiatrists and industry could create
ideas of ethically sound and scientifically justified study
programs and protocols, which fulfil naturalistic treat-
ment conditions.
Finding a way forward
In the light of so many difficult, intertwined and disparate
ethical dilemmas, it is tempting to despair of whether any
psychopharmacological research in children and adoles-
cents can ever be ethically sound. It is important that the
exploration of ethical dilemmas should not end with the
naming of a long list of problems and a metaphorical
wringing of hands, but that some thought and energy
should be given to possible ways forward.
The positive way forward in the development of ethically
sound psychopharmacological research in children and
adolescents is to bring research ethics into the heart of
research development and design itself, rather than just
using research ethics as an oversight mechanism to iden-
tify flaws and potentially block research, as is commonly
the case or perception of researchers. Ethicists themselves
can have a range of attitudes between 'conservative' views
which may tend to protect patients but at the risk of sti-
fling research, to 'liberal' views which may tend to pro-Child and Adolescent Psychiatry and Mental Health 2008, 2:39 http://www.capmh.com/content/2/1/39
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mote research but at the risk of accepting exposure of
patients to more distress or risk. As previously discussed,
past abuse has led to a conservative attitude to research. It
may be time to acknowledge this legacy and to shift to a
more balanced attitude which tries to find a middle
ground between overly conservative and overly liberal
ethical views towards research, and to foster a culture
where both excessive conservatism and liberalism can be
openly challenged and discussed.
In order for ethics to become a helpful and integral part of
research, it is important that there should be a gradual
change in culture and approach involving hearts and
minds, rather than a change in regulations that increases
the burden on researchers. Regulation by its nature is
about ensuring a minimal acceptable standard; in con-
trast, bringing ethics into the heart of research paradigms
should be about creating a maximal, gold standard of eth-
ical and ethically-conducted research.
There are three different and complementary ways in
which this can be achieved:
￿ A comprehensive ethical analysis which takes into
account the different and conflicting ethical principles rel-
evant to psychopharmacological research in children and
adolescents;
￿ Conducting empirical ethics research into issues con-
cerning psychopharmacological research in children and
adolescents; and
￿ Building in ethical thinking and analysis into psychop-
harmacological research in children and adolescents.
i. A comprehensive ethical analysis
Most of the ethical principles which are relevant to psy-
chopharmacological research in children and adolescents
have been developed in other fields and for other situa-
tions, which is why there has been relatively little resolu-
tion of their conflicting implications. For example, the
principle of autonomy was developed for autonomous
adult patients based on an individual autonomy model
which is in turn based on the idea of individual patients
making rational choices. The principle of protection of
children, in contrast, has been developed from a tradition
of protecting children from abuse and exploitation, in a
tradition where children have been seen as having little
voice or control over their situations with respect to adults
who are disposed to harm rather than protect them.
A comprehensive ethical analysis would involve naming
and exploring all the different principles that are relevant
to this field. It would also involve having debates involv-
ing ethicists, researchers, clinicians, policymakers and
patients to decide whether certain principles are impera-
tive and immutable, and if so, which ones; or whether all
the principles are relative and variable. By acknowledging
the difficulties of navigating so many different and often
conflicting principles, it can become possible to explicitly
compare and weigh them against each other, and to be
able to accommodate different situations which may
require different resolutions. For example, should
upholding the notion of 'minimal risk' always be para-
mount? Or are there situations, such as in research with
competent older adolescents and disorders without any
known treatment, where taking greater risks may possibly
be balanced by having greater potential benefits, or where
protection may take second place to fully informed con-
sent and great potential scientific as well as individual
benefit? There needs to be open dialogue and debate
about these tensions, between researchers, ethicists,
research funders and policy-makers.
A final merit of a comprehensive ethical analysis is that
other ethical considerations which have not been promi-
nent in the ethical debates concerning psychopharmaco-
logical research in children and adolescents can be raised.
One example of this is the issue of Altruism. The current
system of ethics oversight of research, in its preoccupation
with protection of research participants, does not allow
for much consideration of altruism on the part of the par-
ticipant. This is particularly the case when the research
participants are considered vulnerable or may lack com-
petence. When this happens, the only rationale which
appears to be an acceptable justification for research is
benefit for the individual or, at most, for others who suffer
from the same condition. People, however, often have
more noble motives. Many children and young people are
highly idealistic and altruistic, and even though their pro-
tection is important, it is also important to allow children
and young people opportunities to develop a sense of cit-
izenship and make contributions to society. Research
shows that children and their parents are prepared to con-
sider undergoing some risk or discomfort in order to par-
ticipate in medical research which would be of benefit to
others but not themselves [60].
ii. Empirical ethics research
Empirical ethics research is a relatively novel field, where
ethicists use empirical research methods to observe the
'real world' dilemmas that occur around particular issues,
and develop ethical analyses based on these research find-
ings. Empirical ethics has the merit of being grounded in
real life ethical dilemmas, as opposed to theoretical rea-
soning of what is morally right or wrong. Theoretical rea-
soning, while very valuable, tends to be dogmatic and
may be experienced as unhelpful or out of touch by those
struggling with complex ethical dilemmas as well as con-
straints such as limited resources. Empirical ethicsChild and Adolescent Psychiatry and Mental Health 2008, 2:39 http://www.capmh.com/content/2/1/39
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research, in contrast, is more likely to capture the full
complexity of their dilemmas and the concurrent con-
straints, and is therefore more likely to be able to generate
helpful analyses and pragmatic suggestions for ethical res-
olution [61].
Examples of empirical ethics research that would be useful
to do are:
￿ Competence to consent to research in children and ado-
lescents who suffer from mental disorders;
￿ The views of children, young people and their parents
about research participation and what the ethical issues
may be for them;
￿ The understanding of the nature of altruism and its place
in psychopharmacological research in children and ado-
lescents;
￿ The experiences of children, young people and their par-
ents in participating in psychopharmacological research;
￿ The ethical dilemmas that research staff and clinical
teams experience in the course of such research.
Such empirical research can be done alongside psychop-
harmacological research in children and adolescents, as
'bolt-on' modules of research which can occur alongside
the core research.
iii. Building in ethical thinking and analysis into 
psychopharmacological research in children and 
adolescents
Researchers, particularly those who labour under strict
ethical oversight systems, may be driven to consider
research ethics as onerous and designed to stifle research.
A more healthy approach is to embrace research ethics
and to consciously design ethical input into research
methodology. This can be done in several ways:
￿ Having a research ethicist involved in developing the
research design can help to ensure the development of
ethical research designs and thoughtful consideration of
the various ethical tensions.
￿ Having a steering group involving patients and parents
can help researchers identify, from their perspective, what
might be the relevant ethical issues, and, equally, what
might be non-issues. The steering group can also help the
researchers to design the study in such a way as to mini-
mize ethical problems.
￿ Having a research ethicist as a consultant during the con-
duct of the study can ensure that any issues that arise can
be considered properly and effectively dealt with.
￿ Having an ethicist on the data management committee
which has oversight of the emerging data; data manage-
ment committees may have to consider issues such as the
welfare of patients in the arm of a study which is showing
less benefit.
￿ Conducting preliminary empirical ethics research, such
as investigating patients' and parents' views of a contro-
versial research design or a potentially risky but beneficial
treatment, may be helpful in determining whether such
research could or should be undertaken, and how this can
best be achieved. Pragmatically, such preliminary research
can also assist in demonstrating to ethics oversight com-
mittees that the ethical ramifications have been taken seri-
ously and adequately explored.
￿ Bolting on empirical research studies to the main study,
as described above, which has a protective effect by ensur-
ing that the ethical dilemmas that emerge are being stud-
ied, in addition to adding to the body of knowledge about
the ethics of research.
Conclusion
Research in psychopharmacology for children and adoles-
cents is fraught with ethical problems and tensions. What
is needed is both an increased awareness of the ethical
issues and tensions which permeate such research, as well
as a willingness to acknowledge these issues and to invest
time and commitment to exploring them. Just as we need
more psychopharmacological research in children and
adolescents in order to develop a sound understanding of
how to best treat children and adolescents with mental
disorders, so we need more ethical analysis and ethics
research in order to develop a sound understand of what
constitutes good, ethical psychopharmacological research
in children and adolescents.
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Appendix 1
Introduction 2. "It is the duty of the physician to promote and
safeguard the health of the people. The physician's knowledge
and conscience are dedicated to the fulfilment of this duty" [1].
Appendix 2
2) Introduction 4. "Medical progress is based on research
which ultimately must rest in part on experimentation involv-
ing human subjects" [1].
Appendix 3
3) Sentence 3 of the preface: "Persons who are incapable of
giving legal consent to clinical trials should be given special pro-
tection. It is incumbent on the Member States to lay down rules
to this effect. Such persons may not be included in clinical trials
if the same results can be obtained using persons capable of giv-
ing consent" [19].
Appendix 4
4) Sentence 3 of the preface of the text of the EU Directive
2001/20: "Normally these persons should be included in clini-
cal trials only when there are grounds for expecting that the
administering of the medicinal product would be of direct ben-
efit to the patient, thereby outweighing the risks." Article 4 of
the Directive: "(g) clinical trials have been designed to mini-
mise pain, discomfort, fear and any other foreseeable risk in
relation to the disease and developmental stage; both the risk
threshold and the degree of distress have to be specially defined
and constantly monitored." Further aspects are found in ICH
E6 §4.8.14 and the U.S. Code of Federal Regulations: Title
45: Public Welfare: 45 C.F.R. §46.405, Research involving
greater than minimal risk but presenting the prospect of
direct benefit to the individual subjects [19-21].
Appendix 5
5) In Re:W (A Minor)(Medical Treatment: Court's Juris-
diction) [1992] WLR 758–782: "Adolescence is a period of
progressive transition from childhood to adulthood and as expe-
rience in life is acquired and intelligence and understanding
grow, so will the scope of decision-making which should be left
to the minor, for it is only in making the decisions and experi-
encing the consequences that decision-making skills will be
acquired. As I put it in the course of the argument and as I sin-
cerely believe, "good parenting involves giving adolescents as
much rope as they can handle without an unacceptable risk that
they will hang themselves"." (Page 770, extract from the
judgement of Lord Donaldson of Lymington, in an Eng-
lish family court case concerning parental consent and
courts overriding the treatment refusal of a 16 year old girl
with anorexia nervosa).
Appendix 6
6) Two examples of differing definitions of decision-mak-
ing in/competence in law are: "incapable of (a) acting; or
(b) making decisions; or (c) communicating decisions; or (d)
understanding decisions; or (e) retaining the memory of deci-
sions." (Adults with Incapacity (Scotland) Act 2000); "a
person is unable to make a decision for himself if he is unable
(a) to understand the information relevant to the decision, (b)
to retain that information, (c) to use or weigh that information
as part of the process of making the decision, or (d) to commu-
nicate his decision (whether by talking, using sign language or
any other means)." (Mental Capacity Act 2005, United
Kingdom)
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